5-溴-2,3-二氟吡啶 | 89402-44-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-溴-2,3-二氟吡啶
• 英文名称: 5-bromo-2,3-difluoropyridine
• 英文别名: 2,3-difluoro-5-bromopyridine
• CAS: 89402-44-8
• 化学式: C₅H₂BrF₂N
• 分子量: 193.978
• InChiKey: QVIQXJRQVOPYGI-UHFFFAOYSA-N

物化性质

• 沸点：
  175 °C
• 密度：
  1.808±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S26,S39
• 危险类别码：
  R22,R37/38,R41
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335
• 储存条件：
  室温环境下。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-2,3-difluoropyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-2,3-difluoropyridine
CAS number: 89402-44-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H2BrF2N
Molecular weight: 194.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-2,3-二氟吡啶 在 四(三苯基膦)钯 、 sodium carbonate 、 一水合肼 作用下， 以 甲醇 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.16h， 生成 8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-thiol
  参考文献：
  名称：

  [EN] 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE
  [FR] 3-(QUINOLIN-6-YLTHIO)-[1,2,4]TRIAZOLO[4,3-A]PYRADINES SUBSTITUÉES EN POSITION 6 À ACTIVITÉ TYROSINE KINASE

  摘要：

  该发明涉及公式(I)化合物及其盐：公式(I)其中的取代基如说明书中所定义；用于治疗人体或动物体的公式(I)化合物，特别是针对c-Met酪氨酸激酶介导的疾病或状况；使用公式(I)化合物来制造治疗此类疾病的药物；包含公式(I)化合物的药物组合物，可选地与联合用药伙伴一起使用，以及制备公式(I)化合物的方法。

  公开号：

  WO2013038362A1
• 作为产物：
  描述：

  2,3,5-三溴吡啶 生成 5-溴-2,3-二氟吡啶
  参考文献：
  名称：

  LITTLE, JOHN C.;WILSON, CHARLES A.

  摘要：

  DOI：

文献信息

• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。
• Enantioselective Three-Component Fluoroalkylarylation of Unactivated Olefins through Nickel-Catalyzed Cross-Electrophile Coupling
  作者：Hai-Yong Tu、Fang Wang、Liping Huo、Yuanbo Li、Shengqing Zhu、Xian Zhao、Huan Li、Feng-Ling Qing、Lingling Chu

  DOI：10.1021/jacs.0c03708

  日期：2020.5.27

  A nickel-catalyzed, enantioselective, three-component fluoroalkylarylation of unactivated alkenes with aryl halides and perfluoroalkyl iodides has been described. This cross-electrophile coupling protocol utilizes a chiral nickel/BiOx system as well as a pendant chelating group to facilitate the challenging three-component, asymmetric difunctionalization of unactivated alkenes, providing direct access

  镍催化、对映选择性、三组分氟烷基芳基化未活化的烯烃与芳基卤化物和全氟烷基碘化物已被描述。这种交叉亲电偶联方案利用手性镍/BiOx 系统以及悬垂的螯合基团来促进未活化烯烃的具有挑战性的三组分不对称双官能化，从而以高效和出色的对映选择性直接获得有价值的手性 β-氟烷基芳基烷烃. 温和的条件允许广泛的底物范围以及良好的官能团耐受性。
• 縮合二環式ヘテロ環誘導体
  申请人：第一三共株式会社

  公开号：JP2016141632A

  公开（公告）日：2016-08-08

  【課題】優れたレチノイン酸受容体関連オーファン受容体γｔ阻害作用を有し、乾癬等の治療薬として有用な化合物の提供。【解決手段】一般式（Ｉ）で表される化合物又はその薬理上許容される塩。［環Ａはピロール環、イミダゾール環又はピラゾール環；環Ｂは置換／非置換のベンゼン環、シクロヘキサジエン環、シクロペンテン環、シクロヘキセン環等；Ｒ１はＨ、ハロゲン原子等；Ｒ２はＨ、ハロゲン原子、Ｃ１−Ｃ６アルキル基等；式＝Ｑ−Ｔ−で表される基は式＝ＣＨ−ＣＨ＝ＣＨ−で表される基等；Ｚは式＝ＣＨ−で表される基等；式−Ｕ−Ｖ（ＣＯ２Ｈ）−Ｗ−で表される基は、式−ＣＨ＝ＣＨ−Ｃ（ＣＯ２Ｈ）＝ＣＨ−で表される基等］【選択図】なし

  提供具有优良的视黄醇酸受体相关孤儿受体γt抑制作用，并且作为银屑病等治疗药物有用的化合物。通式（Ｉ）表示的化合物或其药理上可接受的盐。【环Ａ为吡咯环、咪唑环或吡唑环；环Ｂ为取代/非取代的苯环、环己二烯环、环戊二烯环、环己烯环等；Ｒ₁为Ｈ、卤原子等；Ｒ₂为Ｈ、卤原子、Ｃ₁−Ｃ₆烷基等；基＝Ｑ−Ｔ−表示的基为基＝ＣＨ−ＣＨ＝ＣＨ−等；Ｚ为基＝ＣＨ−等；基表示为式−Ｕ−Ｖ（ＣＯ₂Ｈ）−Ｗ−的基为，基表示为式−ＣＨ＝ＣＨ−Ｃ（ＣＯ₂Ｈ）＝ＣＨ−等】【选择图】无
• Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization
  作者：Tsuyoshi Shinozuka、Tomoharu Tsukada、Kunihiko Fujii、Eri Tokumaru、Kousei Shimada、Yoshiyuki Onishi、Yumi Matsui、Satoko Wakimoto、Masanori Kuroha、Tsuneaki Ogata、Kazushi Araki、Jun Ohsumi、Ryoko Sawamura、Nobuaki Watanabe、Hideki Yamamoto、Kazunori Fujimoto、Yoshiro Tani、Makoto Mori、Jun Tanaka

  DOI：10.1016/j.bmc.2018.09.005

  日期：2018.10

  synthesized compound (II) for the avoidance of hepatotoxicity. The replacement of the left-hand side benzene with 2-pyridine resulted in the substantial loss of potency. Because poor membrane permeability was responsible for poor potency in vitro, the adjustment of lipophilicity was examined, which resulted in the discovery of dimethyl pyridine derivative (I, DS-6930). In preclinical studies, DS-6930 demonstrated

  为了避免肝毒性，尝试降低先前合成的化合物（II）的亲脂性。用2-吡啶代替左手侧苯导致效力的实质损失。由于差的膜通透性导致体外效价差，因此对亲脂性的调节进行了检查，从而发现了二甲基吡啶衍生物（I，DS-6930）。在临床前研究中，DS-6930表现出较高的PPARγ激动剂效价，且血浆葡萄糖降低明显。DS-6930在体内进行毒理学评估后维持与PPARγ相关的副作用减少，并没有显示出肝毒性。辅助因子募集测定表明，显着募集了一些辅助因子，例如RIP140和PGC1，而几个典型因子并未受到影响。这种选择性辅因子募集是由于DS-6930的独特结合模式引起的。钙盐DS-6930b被认为是有效的胰岛素增敏剂，无水肿，可在T2DM患者中进行临床评估。
• [EN] BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS<br/>[FR] DÉRIVÉS BIARYLE EN TANT QU'INHIBITEURS D'INTERACTION PROTÉINE-PROTÉINE YAP/TAZ-TEAD
  申请人：NOVARTIS AG

  公开号：WO2021186324A1

  公开（公告）日：2021-09-23

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

  本发明提供了化合物(I)或其药学上可接受的盐；(I)制造所述化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合物和包括所述化合物的药物组合。